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Effects of daunorubicin, mitomycin C,
azathioprine and cyclosporin A on human retinal
pigmented epithelial, corneal endothelial
and conjunctival cell lines
Abstract Background: We wished to
investigate the toxicity of four immu-
nosuppressant and antimetabolic
drugs, which are known to influence
postoperative wound healing, on three
different human ocular cell lines.
Methods: Acute toxicity to cyclo-
sporin A, azathioprine, mitomicyn C
and daunorubicin was assessed in
Chang cells bymonitoring their uptake
of propidium iodide during a 3-h
period. Chronic toxicity was assessed
by monitoring the proliferation and
viability of subconfluent cultures of
Chang cells, human corneal endothe-
lial cells (HCECs) and retinal pig-
mented epithelial (RPE) cells after
continuous exposure to the drugs for 7
days. Results: Acute toxicity testing
revealed no obvious effects. However,
the chronic toxicity tests disclosed a
narrow concentration range over
which cell proliferation decreased
dramatically but calcein metabolism
was sustained. Although the three
lines reacted similarly to each agent,
HCECs were the most vulnerable to
daunorubicin and mitomycin. At a
daunorubicin concentration of
0.05 μg/ml, a 75% decrease in calcein
metabolism (P<0.001) and a ≥95% cell
loss (P<0.001) were observed. At a
mitomycin concentration of 0.01μg/ml,
cell density decreased by 61%
(P<0.001) without a change in calcein
metabolism, but at 0.1 μg/ml, the
latter parameter decreased to 12%
(P=0.00014). At this concentration the
proliferation of Chang and RPE cells
decreased by more than 50%, whilst
calcein metabolism was largely sus-
tained. Cyclosporin inhibited cell
proliferation moderately at lower con-
centrations (<5 μg/ml; P=0.05) and
substantially at higher ones, with a
corresponding decline in calcein me-
tabolism. Azathioprine induced a pro-
found decrease in both parameters
at concentrations above 5 μg/ml.
Conclusion: Daunorubicin, cyclo-
sporin and azathioprine could be used
to inhibit excessive intraocular scar-
ring after glaucoma and vitreoretinal
surgery without overly reducing cell
viability. The attributes of immuno-
suppressants lie in their combined
antiproliferative and immunomodula-
tory effects.
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Introduction
The control of wound healing after intraocular surgery is
important for the long-term outcome. Numerous antipro-
liferative agents (e.g. cytostatics) have been tested for their
ability to inhibit scar formation after fistulating glaucoma
[16, 21, 25] and vitreoretinal surgery [4, 30].
Today, the drugs of choice in glaucoma surgery are 5-
fluorouracil and mitomycin C. However, neither the opti-
mal mode of application (intraoperatively or during the
early postoperative course) nor the concentration with the
best risk–benefit ratio has been clearly established, which
may have contributed to the unpredictable antiproliferative
effects reported [1, 7, 20].
The capacity of several anti-inflammatory, antiprolifera-
tive and cytotoxic agents to reduce cell proliferation in
association with proliferative vitreoretinopathy (PVR) has
also been investigated. The intravitreal use of long-acting
steroids and steroid-containing drug-delivery systems has
been reported to improve the postoperative course follow-
ing retinal detachment surgery [2, 11, 24]. However, only a
few locally applied antiproliferative drugs, such as dauno-
rubicin, mitomycin and 5-fluorouracil, have so far revealed
sufficiently promising results in the experimental setting to
justify clinical testing [4, 9, 18, 29]. To date, only systemic
corticosteroids are used postoperatively on a standard basis.
None of the other agents investigated has been broadly
applied, owing to their retinotoxicity and other side-effects.
In the present study we investigated the effects of four
established antiproliferative and immunosuppressive drugs
(daunorubicin, mitomycin C, azathioprine and cyclospor-
in A) on the proliferation and metabolism of three different
lines of human ocular cells [Chang, retinal pigmented ep-
ithelial (RPE) and human corneal endothelial cells (HC




Immortalized HCECs had kindly been provided by Prof. K.
Engelmann (University of Dresden) and Dr. J. Bednarz
(University of Hamburg). Corneo-endothelial cells were
used because any antimitotic agent being used in glaucoma
surgery might diffuse into the anterior chamber and thereby
expose the postmitotic corneal endothelium to its toxic
effects. These would thus be deleterious to corneal clarity.
Human RPE cells were collected from several tissue
donors and cultured in vitro. Cells derived from passages
3–5 were used for proliferation and metabolism assays in
order to prevent the functional modifications that might
possibly occur at a later stage of culturing.
Human transfected conjunctival Chang P12 cells were
purchased from ECACC (Salisbury, England).
Each cell line was cultured in MEM (Gibco/Invitrogen
Life Technologies, Basle, Switzerland), which was en-
riched with 10% foetal bovine serum (Gibco) and supple-
mented with L-glutamine (2 mM), penicillin (10,000 U/ml),
streptomycin (10,000 μg/ml) and amphotericin B (25 μg/
ml).The cultures were maintained at 32°C in a humidified
atmosphere containing 5% CO2 until they had attained
subconfluence.
Drugs and experimental set-up
For acute toxicity tests, only the Chang cell line was used.
Each of the four drugs was tested at concentrations of 10,
50 and 100 μg/ml.
For chronic toxicity tests, each of the three cell lines was
used, with drug concentrations of 0.01–50 μg/ml being
investigated. In the absence of other existing data the
chosen concentrations reflect the doses used clinically.
Consequently, they lie well below the expected acute toxic
levels for antimetabolites and immunosuppressants.
Cyclosporin A (Fluka, Buchs, Switzerland) was dis-
solved in 99% ethanol (Hospital Pharmacy, Inselspital
Bern, Switzerland) to a final concentration of 10 mg/ml. It
was further diluted in 50% ethanol to yield a concentration
of 1 mg/ml and in 2.5% ethanol to yield one of 100 μg/ml,
in accordance with the manufacturer’s instructions.
Azathioprine (Sigma/Fluka, Buchs, Switzerland) was
first diluted in 1 M NH3 (Merck, Dietikon, Switzerland), to
yield a concentration of 10 mg/ml, then passed through a
sterile filter [with a pore size of 25 μm (Millipore, Bedford,
Mass., USA)], subsequently diluted in distilled water, and
finally filtered again.
Mitomycin C (Kyowa, Tokyo, Japan) and daunorubicin
(Fluka) were dissolved in distilled water to provide a stock
solution of 2 mg/ml. These solutions were further diluted in
distilled water to provide the appropriate concentrations
and were then filtered under sterile conditions.
For the acute toxicity tests, Chang cells were seeded onto
24-well Costar culture plates at a density of 6,000 cells/
well. For chronic toxicity tests, cells of each line were
seeded at a density of 1,500 cells/well and then grown to
subconfluence overnight, before the experiments were be-
gun. Each experimental condition was tested six times in
parallel. A negative control (using the same diluents as for
the tested drugs) was included in all instances.
Acute toxicity tests
Acute toxicity tests were run only on Chang cells, an ocular
fibroblast line. Little additional information was expected
from acute toxicity testing on the other cell lines, since the
drug concentrations, having been chosen with a view to
clinical application, lay below the expected acute toxicity
levels. Furthermore, experiments for chronic toxicity re-
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vealed no marked differences between the analysed cell
lines at the tested drug concentrations.
Acute toxicity was assessed by the propidium-iodide
assay. Propidium iodide enters non-viable cells and binds
irreversibly to their nuclei, whereupon it acts as a fluo-
rescent dye. The amount of bound propidium iodide was
quantified by measurement of the fluorescence in a Cyto-
fluor (Millipore), using an excitation/emission wavelength-
coupling of 530/645 nm [28].
For this purpose, cell monolayers were incubated with
1 ml of serum-free MEM containing propidium iodide
(20 μg/ml) and the drug to be tested. Fluorescence was
measured every 15 min during the first hour and every
30 min during the following 3 h. The cells were then
incubated for 1 h with 1 ml of 1.5% Tween 20 (Gibco/
Invitrogen Life Technologies) to permeabilize the cell
membranes and yield the (maximal) endpoint fluorescence.
Toxicity was expressed as the quotient of the experimental
fluorescence (for each drug and concentration) and the
endpoint fluorescence.
Chronic toxicity tests
Chronic toxicity was assessed by the decreases in cell-
esterase activity and cell growth after 7 days of continuous
exposure to the test drug. The drug-containing culture me-
dium was changed after 4 days. Seven days represents the
maximum time-span elapsing before cell overgrowth ren-
ders counting very difficult and imprecise. This time-span
is also reasonable from a clinical viewpoint, since it cor-
responds to the critical period of postsurgical wound heal-
ing, i.e. that which determines the ultimate success or
failure of an operation.
Cell-esterase activity and cell-viability testing
Calcein-AM (Molecular Probes Europe, Leiden, Netherlands),
a fluorogenic esterase substrate, is converted intracellularly
by a cytoplasmic esterase. Calcein is a membrane-imper-
meable green fluorescent dye, which is retained only by
viable cells. It was quantified by measurement of the fluo-
rescence emitted at 485 nm in a Cytofluor (Millipore).
Cell monolayers were gently washed in phosphate-
buffered saline (PBS) and then incubated with 200 μl of
MEM (without phenol red), containing 1.5 μM calcein-
AM, for 30 min. They were then carefully rinsed twice and
covered with 500 μl of MEM (without phenol red) for the
fluorescent measurement of calcein uptake and activation.
Following this measurement, the supernatant containing
dead, unattached cells was discarded. The monolayers of
living cells were then gently washed, trypsinized and har-





















































Fig. 1 a Proliferation assay with
daunorubicin. The numerical
density of the three cell lines
measured after 7 days of incu-
bation with various concentra-
tions is expressed as a percentage
of the density obtained without
the drug. Values represent the
mean (± SD) of the six experi-
ments. *P<0.05. b Calcein-AM
assay for chronic toxicity with
daunorubicin. The esterase ac-
tivity of the three cell lines after
incubation with various concen-
trations for 7 days is shown as a
percentage of the maximal fluo-
rescence (incubation without
drug). All values are the mean
(± SD) of the six experiments.
*P<0.05
384
a cell counter calibrated for this purpose (Sysmex Europe,
Norderstedt, Germany).
Statistical evaluation
Data presented represent the average of six experiments in
each group. Fluorescence measurements and cell counts
were compared statistically by the application of Student’s
t-test, using Bonferroni’s correction to highlight significant
differences (P<0.05) between the values.
Results
Acute toxicity
Acute toxicity testing of the four agents on Chang cells
revealed few or no deleterious effects within the clinically
relevant concentration range. At a concentration of, or
above, 50 μg/ml, cyclosporin A elicited an increase in cell
death after an exposure time of 90 min. Neither azathio-
prine nor mitomycin C induced a cytotoxic effect at any
time during the experimental time course or at any of the
tested concentrations. Daunorubicin was similarly impotent
in the concentration range 0.1–10 μg/ml (data not shown).
Chronic toxicity
The chronic toxicity of the four agents was assessed in each
of the three cell lines by the monitoring of proliferation
(cell count) and calcein metabolism after 7 days of con-
tinuous exposure.
Daunorubicin
HCECs were the most vulnerable of the three cell lines. At
a concentration of 0.05 μg/ml, daunorubicin elicited a
decrease in calcein metabolism of 75% (P=0.000079) and a
cell loss of more than 95% (P=0.000079). In the RPE and
Chang cell lines these parameters underwent a less pro-
nounced decline at a drug concentration of 0.5 μg/ml, with
cell density being more susceptible than calcein metabo-
lism (Fig. 1).
Mitomycin C
As with daunorubicin, HCECs were the most vulnerable
of the three cell lines. At a mitomycin concentration of
0.01 μg/ml, cell density decreased by 61% (P=0.000079),



















































Fig. 2 a Proliferation assay with
mitomycin. The numerical den-
sity of the three cell lines mea-
sured after 7 days of incubation
with various concentrations is
expressed as a percentage of the
density obtained without the
drug. Values represent the mean
(± SD) of the six experiments.
*P<0.05. b Calcein-AM assay
for chronic toxicity with mito-
mycin. The esterase activity of
the three cell lines after incuba-
tion with various concentrations
for 7 days is shown as a percen-
tage of the maximal fluorescence
(incubation without drug). All
values are the mean (± SD) of the
six experiments. *P<0.05
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er, when the mitomycin concentration was raised to 0.1 μg/
ml, the latter parameter dropped to 12% (P=0.00014).
Above concentrations of 0.05 μg/ml and 0.1 μg/ml, the
density of Chang and RPE cells decreased by more than
70% and 50%, respectively, whereas calcein metabolism
was largely unaffected [although the differences were sta-
tistically significant: for Chang cells, P=0.0172; for RPE
cells, P=0.0136 (Fig. 2)].
Cyclosporin A
All three cell lines responded similarly to cyclosporin A. At
concentrations below 5 μg/ml this drug did not inhibit cell
proliferation significantly (P=0.05), whereas above 5 μg/
ml, a substantial reduction in this parameter was observed.
At 50 μg/ml cell proliferation in each of the cell lines was
inhibited by more than 80%. In the RPE cells and HCECs,
changes in calcein metabolism corresponded to those in
cell density. Interestingly, calcein metabolism in the Chang
cells was still unaffected at a cyclosporin concentration of
5 μg/ml, whereas cell proliferation had already decreased
by more than 20% (P=0.005). However, at concentrations
above 5 μg/ml, both cell proliferation and cell metabolism
underwent a substantial decline (Fig. 3).
Azathioprine
For HCECs and Chang cells the azathioprine-induced
changes in cell proliferation and calcein metabolism were
similar, with both parameters decreasing sharply at concen-
trations above 5 μg/ml. At 50 μg/ml, Chang cell prolif-
eration tended to be inhibited more markedly than calcein
metabolism (Fig. 4).
At a drug concentration of 5 μg/ml, calcein metabolism
in RPE cells decreased significantly without a decline in
cell proliferation. However, at concentrations above 5 μg/ml,
both calcein metabolism and cell proliferation were substan-
tially inhibited.
Discussion
Our findings reveal that the proliferation and metabolism
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Fig. 3 a Proliferation assay with
cyclosporin A. The numerical
density of the three cell lines
measured after 7 days of incu-
bation with various concentra-
tions is expressed as a percentage
of the density obtained without
the drug. Values represent the
mean (± SD) of the six experi-
ments. *P<0.05. b Calcein-AM
assay for chronic toxicity with
cyclosporin A. The esterase ac-
tivity of the three cell lines after
incubation with various concen-
trations for 7 days is shown as a
percentage of the maximal fluo-
rescence (incubation without
drug). All values are the mean
(± SD) of the six experiments.
*P<0.05
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influences, the former being more susceptible (occurring at
lower concentrations) than the latter. For each of the agents
tested, HCECs were more vulnerable than either the RPE
or Chang lines. Our data also suggest that the immuno-
modulatory drug cyclosporin A may be a suitable candidate
for the control of wound healing. Apart from having a
direct impact on cell proliferation, this drug is also capable
of modulating the postoperative inflammatory tissue re-
action and, thus, of controlling wound healing.
Acute toxicity testing revealed no significant effects of
any of the agents, even at concentrations of up to 100 μg/
ml. Hence, the chosen doses met our expectations for acute
subthreshold cytotoxic levels. These findings correspond
to those reported by other investigators. For example, at
mitomycin concentrations up to 10 μg/ml, even fibroblasts
retained their ability to proliferate [7]. In addition, over the
same range, cyclosporin A similarly failed to inhibit the
proliferation of human conjunctival fibroblasts [10].
Mitomycin C has already been shown to efficiently
inhibit postoperative scarring in high-failure-risk patients
who have undergone glaucoma surgery [3, 7]. In addition,
after photokeratectomy with the excimer laser [19, 23], a
dose-dependent inhibition of fibroblast proliferation has
been reported for this drug. However, the efficacy of
mitomycin in preventing scarring after trabeculectomy is
compromised by the high rate of complications, such as
persistent hypotony, thin avascular cystic blebs and en-
dophthalmitis [12, 22]. In refractive surgery, local side-ef-
fects, such as superficial punctuate keratopathy, recurrent
corneal epithelial defects, iridocyclitis and scleral melting,
have been observed [17]. In our study, the proliferation of
HCECs was highly susceptible to mitomycin. At a drug
concentration of only 0.01 μg/ml, this parameter decreased
by 61%. On the other hand, calcein metabolism was still
above 80% at this concentration, thereby indicating a
possible therapeutic window. In glaucoma surgery, mito-
mycin concentrations between 0.1 mg/ml and 0.5 mg/ml
are most commonly used but with variations in application
time and the mode of application [1, 3, 8, 13]. On the basis
of our findings, a concentration of 1.0 μg/ml would be
suitable to prevent the proliferation of RPE cells and PVR
without untoward toxic effects.
Cyclosporin A inhibited proliferation in each of the three
cell lines at concentrations of up to 5 μg/ml, which had no
profound effect on cell metabolism. At 5 μg/ml, the density




















































Fig. 4 a Proliferation assay with
azathioprine. The numerical
density of the three cell lines
measured after 7 days of incu-
bation with various concentra-
tions is expressed as a percentage
of the density obtained without
the drug. Values represent the
mean (± SD) of the six experi-
ments. *P<0.05. b Calcein-AM
assay for chronic toxicity with
azathioprine. The esterase activ-
ity of the three cell lines after
incubation with various concen-
trations for 7 days is shown as a
percentage of the maximal fluo-
rescence (incubation without
drug). All values are the mean
(± SD) of the six experiments.
*P<0.05
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calcein metabolism was not affected. In vivo studies sup-
port the use of topical 2% cyclosporin in trabeculectomy
surgery, the control of intraocular pressure being compa-
rable to that achieved with mitomycin C [27]. Together with
preliminary clinical evidence, our findings justify a contin-
ued search for other immunosuppressants with a greater
capacity to inhibit cell proliferation but with a correspond-
ingly acceptable cell-toxicity profile. However, several re-
cent studies indicate that the inhibition of cell proliferation
alone may not suffice to hinder postoperative scarring,
since growth-arrested fibroblasts can still influence this
process—either directly or indirectly—via the production
of regulatory proteins [5, 16]. The use of immunosuppres-
sants rather than antiproliferative cytotoxic agents (either
alone or adjunctively) [6, 15, 26] could be advantageous in
this respect, owing to their combined antiproliferative and
immunomodulatory effects [31].
Due to their unphysiological pH values, preparations of
azathioprine have not been applied to control ocular wound
healing in vivo. In the present study, this drug inhibited cell
proliferation more profoundly than calcein metabolism in
HCECs and Chang cells at a concentration of 50 μg/ml.
For each of the four agents tested there existed a narrow
concentration range over which cell proliferation was in-
hibited substantially without a marked reduction in calcein
metabolism, which is a desirable effect for a drug applied
immediately after glaucoma and retinal surgery (i.e., during
the wound-healing phase). Critics might question the val-
idity of this test result, arguing that a reduction in calcein
metabolism is the sum of proliferation inhibition and cell
toxicity. However, other studies have shown that calcein
metabolism does not decrease in direct proportion to the
decline in cell number, especially near the IC-50 range (i.e.,
that at which 50% of the cells are inhibited), where calcein
metabolism peaks before decreasing sharply. This phe-
nomenon has been attributed to a selective activation of ion
channels in the surviving cell population [32]. Never-
theless, other metabolic functions of cultured cells should
now be assessed to validate the surprisingly narrow ther-
apeutic window observed in our study, experience having
taught us that the window is equally narrow in the clinical
setting.
To the best of our knowledge no previous study has
directly compared the effects of more than one antiproli-
ferative agent on three different human cell lines, and our
data may thus be more applicable to the clinical setting than
those emanating from non-human cell experiments. Further-
more, we assessed the potential benefits of the antiproli-
ferative agents in terms not only of their dose-dependent
effects on cell proliferation but also of their metabolic ef-
fects on the surviving cell population. In this latter context,
cytoplasmic esterase activity is deemed to be a representa-
tive marker [14, 32].
An in vitro assessment of cell proliferation and viability
permits a preselection of the most promising drugs. Only
these need to be tested in animal experiments, the number
of which can thus be drastically reduced. Nevertheless,
there is no way that any drug tested in vitro could then be
used in humans without previous extensive animal testing,
though the in vitro studies may set the stage for the dimen-
sions of animal testing.
A drawback of our study was the limited concentration
range of the drugs tested. For this reason, it was not
possible to calculate the IC-50 values. Similarly, we were
unable to establish the drug concentration at which toxic
effects began after only a short exposure time (acute tox-
icity testing).
In summary, our results indicate that cyclosporin A,
azathioprine and daunorubicin may represent a group of
substances that could be employed, either alone or in
combination, to optimize the wound-healing process after
glaucoma or vitreoretinal surgery by inhibiting excessive
scarring without overly reducing cell viability. However, in
vivo studies are now required to optimize the drug dose as
well as the mode and duration of application. The search
for other pharmacological agents, that are capable of con-
trolling the postoperative scarring response and, ideally,
also the postoperative inflammatory tissue response with-
out unsupportable adverse complications in these surgical
settings, should continue.
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